Alnylam Pharma (ALNY) Tops Q1 EPS by 108c, provides guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $249.59 +1.25%
Revenue Growth %: +15.3%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +15.3%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of $1.99, $1.08 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.12 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.56 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Costco (COST) Tops Q4 EPS by 20c
- Anthropic seeks founder voting control structure ahead of IPO - The Information
- Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
